The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers: methodological update
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers: methodological update
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-03-10
DOI
10.1007/s00259-020-05120-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives
- (2021) Matteo Cotta Ramusino et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
- (2021) N. J. Ashton et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework
- (2021) E. E. Wolters et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- 2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
- (2021) A. Leuzy et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
- (2021) Gérard N Bischof et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
- (2021) Konstantinos Chiotis et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes
- (2020) Adam S. Fleisher et al. JAMA Neurology
- Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease
- (2020) Simon Dujardin et al. NATURE MEDICINE
- NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
- (2018) Clifford R. Jack et al. Alzheimers & Dementia
- Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia
- (2018) Marina Boccardi et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers
- (2017) Giovanni B Frisoni et al. LANCET NEUROLOGY
- The biomarker-based diagnosis of Alzheimer's disease. 2—lessons from oncology
- (2017) Marina Boccardi et al. NEUROBIOLOGY OF AGING
- Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework
- (2017) Valentina Garibotto et al. NEUROBIOLOGY OF AGING
- Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: an Italian intersocietal roadmap
- (2017) Giovanni B. Frisoni et al. NEUROBIOLOGY OF AGING
- Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework
- (2017) Konstantinos Chiotis et al. NEUROBIOLOGY OF AGING
- Clinical validity of delayed recall tests as a gateway biomarker for Alzheimer's disease in the context of a structured 5-phase development framework
- (2017) Chiara Cerami et al. NEUROBIOLOGY OF AGING
- The biomarker-based diagnosis of Alzheimer's disease. 1—ethical and societal issues
- (2017) Corinna Porteri et al. NEUROBIOLOGY OF AGING
- Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework
- (2017) Mara ten Kate et al. NEUROBIOLOGY OF AGING
- Clinical validity of presynaptic dopaminergic imaging with 123 I-ioflupane and noradrenergic imaging with 123 I-MIBG in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies in the context of a structured 5-phase development framework
- (2017) Ida Sonni et al. NEUROBIOLOGY OF AGING
- Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework
- (2017) Niklas Mattsson et al. NEUROBIOLOGY OF AGING
- TDP-43 stage, mixed pathologies, and clinical Alzheimer’s-type dementia
- (2016) Bryan D. James et al. BRAIN
- The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey
- (2015) Martina Bocchetta et al. Alzheimers & Dementia
- The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity
- (2015) Giovanni B. Frisoni et al. Alzheimers & Dementia
- Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
- (2014) Bruno Dubois et al. LANCET NEUROLOGY
- Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series
- (2013) Gabor G. Kovacs et al. ACTA NEUROPATHOLOGICA
- QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies
- (2013) Penny F. Whiting ANNALS OF INTERNAL MEDICINE
- Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2012
- (2013) M. A. Leone et al. EUROPEAN JOURNAL OF NEUROLOGY
- Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010
- (2012) Thomas G. Beach et al. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
- The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
- (2011) Guy M. McKhann et al. Alzheimers & Dementia
- The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
- (2011) Marilyn S. Albert et al. Alzheimers & Dementia
- GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
- (2011) Gordon Guyatt et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)
- (2011) Gordon H. Guyatt et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
- (2010) Christopher C. Rowe et al. NEUROBIOLOGY OF AGING
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment
- (2008) Clifford R. Jack et al. BRAIN
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started